NUTEX Investments (BUD:NUTEX) Altman Z2-Score: 171.96 (As of Jul. 03, 2026) — 53% Below Median


BUD:NUTEX NUTEX Investments PLC BUD:NUTEX
50 GF Score
Price Ft13.40
GF Value Ft13.80
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is NUTEX Investments Altman Z2-Score?

NUTEX Investments BUD:NUTEX -0.37% 50 Altman Z2-Score is 171.96 as of Jul. 03, 2026, which is 53% below its 10-year median of 366.41. GuruFocus rates BUD:NUTEX with a GF Score™ of 50/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, NUTEX Investments ranks better than 99.7% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

NUTEX Investments has a Altman Z2-Score of 171.96, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for NUTEX Investments's Altman Z2-Score or its related term are showing as below:

BUD:NUTEX' s Altman Z2-Score Range Over the Past 10 Years
Min: 3.31   Med: 366.41   Max: 1098.63
Current: 171.96

During the past 13 years, NUTEX Investments's highest Altman Z2-Score was 1098.63. The lowest was 3.31. And the median was 366.41.


NUTEX Investments  (BUD:NUTEX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


NUTEX Investments Altman Z2-Score Related Terms


NUTEX Investments Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for NUTEX Investments's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NUTEX Investments Altman Z2-Score Chart

NUTEX Investments Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,098.63 560.85 663.54 132.39 171.96

NUTEX Investments Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 663.54 0.00 132.39 0.00 171.96

BUD:NUTEX vs ZTS, UTHR, VTRS: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NUTEX Investments Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where NUTEX Investments's Altman Z2-Score falls into.


BUD:NUTEX
50GF Score
NUTEX Investments PLC BUD:NUTEX
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NUTEX Investments Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

NUTEX Investments's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.9935+3.26*0.8046+6.72*0.0978+1.05*154.4413
=171.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was Ft5,555.28 Mil.
Total Current Assets was Ft5,555.06 Mil.
Total Current Liabilities was Ft35.72 Mil.
Retained Earnings was Ft4,469.51 Mil.
Pre-Tax Income was Ft543.03 Mil.
Interest Expense was Ft0.00 Mil.
Total Liabilities was Ft35.72 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(5555.057 - 35.718)/5555.28
=0.9935

X2=Retained Earnings/Total Assets
=4469.509/5555.28
=0.8046

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(543.032 - 0)/5555.28
=0.0978

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(5516.546 - 0.21)/35.718
=154.4413

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

NUTEX Investments has a Altman Z2-Score of 171.96 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 171.96 mean?
NUTEX Investments (BUD:NUTEX) has a Altman Z2-Score of 171.96 as of Jul. 03, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on NUTEX Investments and its competitors. This is 53% below median its historical median of 366.41. Over the past decade, NUTEX Investments' Altman Z2-Score has ranged from 3.31 to 1,098.63. According to the industry distribution chart, NUTEX Investments ranks #3 out of 996 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is NUTEX Investments' Altman Z2-Score too high?
NUTEX Investments' current Altman Z2-Score of 171.96 is 53% below median its 10-year median of 366.41. Over the past 10 years, this metric has ranged from a low of 3.31 to a high of 1,098.63. The Drug Manufacturers industry median Altman Z2-Score is 3.87. NUTEX Investments' value of 171.96 is 4349.2% above this industry median. Based on the distribution chart, NUTEX Investments ranks #3 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #3 out of 996 companies for Altman Z2-Score. This places NUTEX Investments in the top 0% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.87. NUTEX Investments' value of 171.96 is 4349.2% above this benchmark. Historically, NUTEX Investments' own Altman Z2-Score has ranged from 3.31 to 1,098.63 over the past decade. While the company's 10-year median is 366.41 vs. the industry median of 3.87, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Altman Z2-Score of 171.96 is 4349.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Altman Z2-Score is 171.96, which is 53% below median its own 10-year median of 366.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current Altman Z2-Score is 171.96, which is 53% below median its 10-year median of 366.41 and 4349.2% above the Drug Manufacturers industry median of 3.87. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Altman Z2-Score is 171.96 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?

Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued. The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80. GuruFocus considers NUTEX Investments to be Fairly Valued.

Key valuation signals for BUD:NUTEX:

  • Altman Z2-Score: 171.96 (53% below median its 10-year median of 366.41)
  • GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
  • GF Score™: 50/100 with 3 warning signs
  • Industry Position: 4349.2% above the Drug Manufacturers median (#3 of 996)

No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NUTEX Investments Business Description

Address Telepes u. 53., Budapest, HUN, 1147
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score

Get the complete analysis for BUD:NUTEX

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Ft13.40
Price
Ft13.80
GF Value